>>Signaling Pathways>> GPCR/G protein>> Ras>>RAS inhibitor Abd-7

RAS inhibitor Abd-7

Catalog No.GC62421

강력한 RAS-결합 화합물(Kd=51nM)인 RAS 억제제 Abd-7은 RAS-이펙터 단백질-단백질 상호작용(PPI) 억제제입니다. RAS 억제제 Abd-7은 세포 내부의 RAS와 상호작용하고, RAS-이펙터 상호작용을 방지하고, 내인성 RAS 의존적 신호전달을 억제합니다. RAS 억제제 Abd-7은 PI3K, CRAF 및 RALGDS뿐만 아니라 NRAS Q61H 및 HRAS G12V를 사용하여 다양한 돌연변이 KRAS 단백질의 PPI를 손상시킵니다.

Products are for research use only. Not for human use. We do not sell to patients.

RAS inhibitor Abd-7 Chemical Structure

Cas No.: 2351843-48-4

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$347.00
재고 있음
5 mg
US$315.00
재고 있음
10 mg
US$495.00
재고 있음
25 mg
US$855.00
재고 있음
50 mg
US$1,305.00
재고 있음
100 mg
US$2,025.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V[1].

RAS inhibitor Abd-7 (0-20 μM; 24-48 hours) is a cell-potent inhibitor affecting the viability of cancer cell lines in a single digit to low micromolar range[1].

[1]. Quevedo CE, et al. Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nat Commun. 2018;9(1):3169. Published 2018 Aug 9.

리뷰

Review for RAS inhibitor Abd-7

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RAS inhibitor Abd-7

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.